Vitamin C’s on-again, off-again reputation as a cancer fighter has a new twist: researchers now think that at very high doses it works in the opposite way to how it was long imagined.
The reversal
Vitamin C is famous as an antioxidant. But at the extremely high concentrations reached only through intravenous delivery — especially around tumours — it can flip roles and act as a pro-oxidant, generating hydrogen peroxide.
That inversion sounds paradoxical and is well established in chemistry. Antioxidants work by donating electrons to neutralise reactive molecules, and in doing so they become mildly reactive themselves. At ordinary concentrations that is inconsequential. At very high concentrations, in the presence of metal ions found in tissue, the reaction can run the other way and generate reactive oxygen species rather than quench them.
The molecule has not changed. The concentration has, and concentration determines which chemistry dominates.
Why tumour cells are more vulnerable
Hydrogen peroxide tends to damage cancer cells more than normal ones, because tumour cells are already metabolically stressed, grow fast, have poor blood supply and weaker internal cleanup systems.
Each factor compounds the others. Rapid growth generates reactive byproducts continuously, so tumour cells operate closer to their oxidative tolerance before anything is added. Disorganised tumour blood vessels deliver oxygen and nutrients unevenly, leaving regions under further stress. And reduced capacity in the enzymes that neutralise peroxide — catalase in particular — means less ability to clear what arrives.
A cell already near its limit fails when pushed; a healthy cell with intact defences absorbs the same insult. That margin is the entire therapeutic premise.
Why the route of administration is decisive
The doses required cannot be reached with tablets — only carefully controlled IV administration achieves them.
This is not a matter of taking enough pills. Absorption of vitamin C from the gut is actively regulated by transporters that saturate, so beyond a modest oral dose the additional amount is simply not absorbed. Blood levels plateau regardless of how much more is swallowed, and the excess is excreted.
Intravenous delivery bypasses that limit entirely, producing concentrations that are orders of magnitude higher and physiologically unreachable by mouth.
The consequence is that oral and intravenous vitamin C are, functionally, different interventions. Evidence about one says nothing about the other — which is a large part of why the historical literature on vitamin C and cancer is so contradictory.
What the evidence shows
The effect has been seen in lab studies and small human trials across various cancers. Patients given intravenous vitamin C alongside chemotherapy have reported less fatigue, pain and nausea — but whether it extends survival remains unproven, with mixed results.
The distinction between those two findings deserves emphasis. Improved tolerability is a real and worthwhile outcome, and it is also the outcome most vulnerable to placebo effects, since it is self-reported and patients receiving an additional infusion know they are receiving something.
Survival is the harder endpoint and the one that has not been demonstrated.
The history behind the controversy
Vitamin C and cancer has an unusually fraught research record, which explains present caution.
Claims of dramatic benefit in the 1970s, championed by a prominent scientist, were followed by rigorous trials that found nothing. Those trials used oral vitamin C, and the field largely closed the question.
The renewed interest rests on the argument that oral dosing tested a different intervention from the one originally described — a defensible point, and one that also illustrates how a well-intentioned methodological choice can settle a question incorrectly for decades.
The crucial caveat
This remains experimental. It belongs in clinical trials or supervised medical settings, not commercial wellness clinics selling infusions.
That warning is pointed for a reason: IV vitamin C is already sold widely outside any research context, at clinics making claims the evidence does not support. High-dose infusions are not risk-free — they can precipitate severe complications in people with certain enzyme deficiencies or kidney impairment.
Why the trials are hard to fund
The persistent gap between mechanistic plausibility and definitive evidence here is partly economic rather than scientific.
Vitamin C cannot be patented. Any company running the large randomised trial needed to establish a survival benefit would be funding evidence that every competitor could use, with no exclusivity to recover the cost. That removes the mechanism that funds most late-stage cancer trials.
Academic and government funders can in principle fill the gap, and they operate at smaller scale and face competing priorities. The result is a literature of small trials — adequate to detect symptom differences, underpowered for survival — which is precisely the pattern observed.
That is worth separating from the science. A treatment lacking definitive evidence because the trial has not been funded is in a different position from one where the trial was run and found nothing, and readers encountering strong claims in either direction should know which situation applies.
Vitamin C is not a proven cancer treatment. This explains ongoing research and is not medical advice. Do not use high-dose vitamin C to treat any condition without a qualified oncologist’s supervision.